| sunitinib / Generic mfg. |
NCT00378911: Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus |
|
|
| Completed | 2 | 44 | US | sunitinib malate, SU11248, sunitinib, Sutent | National Cancer Institute (NCI), Gynecologic Oncology Group | Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma | 06/07 | 01/10 | | |
NCT00137449 / 2005-001303-19: Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor |
|
|
| Completed | 2 | 60 | US, Europe | SU011248 | Pfizer | Gastrointestinal Stromal Tumors | 04/08 | 04/08 | | |
| Terminated | 2 | 13 | US | Nilotinib, Tasigna | Fox Chase Cancer Center | Gastrointestinal Stromal Tumors | 07/08 | 10/09 | | |
NCT00570635: A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib |
|
|
| Completed | 2 | 16 | US | XL820 | Exelixis | Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms | 05/09 | 05/09 | | |
NCT00499473: Sunitinib in Treating Patients With Recurrent Malignant Gliomas |
|
|
| Completed | 2 | 31 | US | sunitinib malate, SU11248, sunitinib, Sutent, pharmacological study, pharmacological studies | National Cancer Institute (NCI) | Adult Anaplastic Astrocytoma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Pineal Gland Astrocytoma | 06/09 | 10/14 | | |
NCT00265798: Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
|
|
| Active, not recruiting | 2 | 38 | US | Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54 9085, BAY 54-9085, BAY 549085, BAY-54-9085, BAY549085, Nexavar, sorafenib | National Cancer Institute (NCI) | Gastrointestinal Stromal Tumor | 02/10 | 03/25 | | |
NCT00618319: An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) |
|
|
| Completed | 2 | 20 | US | BIIB021, CNF2024 | Biogen | GIST | 04/10 | 04/10 | | |
NCT00521092: Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma |
|
|
| Withdrawn | 2 | 0 | US | sunitinib malate, SU11248, sunitinib, Sutent, laboratory biomarker analysis, pharmacological study, pharmacological studies | National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID) | AIDS-related Kaposi Sarcoma, Classic Kaposi Sarcoma | 10/10 | | | |
NCT00474994: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas |
|
|
| Completed | 2 | 53 | US | sunitinib malate | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Dana-Farber Cancer Institute | Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer, Sarcoma, Small Intestine Cancer | 11/10 | 11/10 | | |
| Completed | 2 | 39 | RoW | Sorafenib | Samsung Medical Center, Korean GIST Study Group | Gastrointestinal Stromal Tumors | 12/10 | 08/11 | | |
|
NCT01506336: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib |
|
|
| Completed | 2 | 44 | Europe | masitinib, sunitinib | AB Science | Gastro Intestinal Stromal Tumor | 09/11 | 04/12 | | |
|
|
NCT00400569: Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma |
|
|
| Completed | 2 | 48 | US | Sunitinib Malate (SU011248), Sutent, SU011248 | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Liposarcoma, Leiomyosarcoma, Fibrosarcoma, Malignant Fibrous Histiocytoma | 12/11 | 12/11 | | |
NCT01039519: A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) |
|
|
| Completed | 2 | 27 | US | Ganetespib, STA-9090 | Synta Pharmaceuticals Corp. | Gastrointestinal Stromal Tumor | 12/11 | 12/11 | | |
NCT01068769: Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor |
|
|
| Completed | 2 | 34 | US | regorafenib, Stivarga | Suzanne George, MD, Brigham and Women's Hospital, Massachusetts General Hospital, Fox Chase Cancer Center, Oregon Health and Science University, Bayer | Gastrointestinal Stromal Tumor | 06/12 | 08/20 | | |
|
NCT00859456: Sunitinib in Certain Subtypes of Soft Tissue Sarcomas |
|
|
| Terminated | 2 | 10 | US | Sunitinib, Sutent, Sunitinib malate, SU011248 | Columbia University | Sarcoma, Soft Tissue | 11/12 | 02/13 | | |
NCT01440959: Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 |
|
|
| Completed | 2 | 30 | RoW | dovitinib, A phase II study of TKI258 | Asan Medical Center | Gastrointestinal Stromal Tumors | 03/13 | 03/13 | | |
|
NCT00718562: Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib |
|
|
| Completed | 2 | 35 | Japan | AMN107 | Novartis Pharmaceuticals | Gastrointestinal Stromal Tumors | 07/13 | 07/13 | | |
|
NCT00556049: Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma |
|
|
| Completed | 2 | 72 | US | Gemcitabine, Gemzar, Sunitinib, Sutent | Massachusetts General Hospital, Pfizer, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute | Renal Cell Carcinoma, Neoplasm Metastases | 12/13 | 12/14 | | |
|
|
| Completed | 2 | 81 | Europe | Pazopanib, Best supportive care | Centre Leon Berard, GlaxoSmithKline | GIST | 04/14 | 02/16 | | |
|
| Completed | 2 | 72 | Europe | Pazopanib, Votrient | Scandinavian Sarcoma Group, GlaxoSmithKline | Gastrointestinal Stromal Tumors | 01/15 | 11/16 | | |
NCT01389583: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients |
|
|
| Unknown status | 2 | 25 | RoW | AUY922 | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Taichung Veterans General Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Chang Gung Memorial Hospital | Gastrointestinal Stromal Tumor | 05/15 | 10/19 | | |
NCT06390826: Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) |
|
|
| Active, not recruiting | 2 | 35 | US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radionuclide Imaging, NM, Nuclear Medicine, nuclear medicine scan, radioimaging, Radionuclide Scanning, Scan, Scintigraphy, Sunitinib | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 03/25 | 03/25 | | |
2008-000756-27: Activity of sunitinib in esophageal cancer, melanoma and sarcoma. |
|
|
| Ongoing | 2 | 96 | Europe | Sutent, Sutent | UZ Brussel | Patients with advanced esophageal cancer, melanoma and sarcoma. | | | | |
| Completed | 2 | 29 | Europe | PD 0332991 | Institut Bergonié | Advanced Gastrointestinal Stromal Tumors | 12/16 | 02/19 | | |
| Completed | 2 | 71 | Europe | Everolimus, RAD001 | Novartis Pharmaceuticals | Progressive Sarcoma | 05/17 | 05/17 | | |
| Completed | 2 | 6 | US, Europe, RoW | sunitinib malate dose escalation, sunitinib malate | Pfizer | Gastrointestinal Stromal Tumors | 08/17 | 08/17 | | |
NCT02889328: Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs |
|
|
| Completed | 2 | 25 | RoW | Regorafenib | Asan Medical Center | Gastrointestinal Stromal Tumors (GISTs) | 08/17 | 01/18 | | |
NCT02607332: Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib |
|
|
| Completed | 2 | 25 | RoW | Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 01/18 | 01/18 | | |
| Unknown status | 2 | 81 | Europe | Ponatinib 30 MG, Iclusiq | Sebastian Bauer, Hannover Medical School, Helios Klinikum Berlin-Buch, University Hospital Tuebingen, Universitätsmedizin Mannheim, University Hospital, Aachen, Helios Klinikum Bad Saarow, WiSP GmbH | GIST, Malignant, KIT Exon 13 Mutation, KIT Gene Mutation | 09/18 | 09/20 | | |
NCT00478426: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
|
|
| Completed | 2 | 34 | Canada, US | Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent | National Cancer Institute (NCI) | Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma | 02/19 | 02/19 | | |
| Completed | 2 | 51 | Europe, RoW | cabozantinib | European Organisation for Research and Treatment of Cancer - EORTC | Metastatic Gastrointestinal Stromal Tumor | 05/19 | 02/21 | | |
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig |
|
|
| Not yet recruiting | 2 | 30 | Europe | Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo | Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark | Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04] | | | | |
NCT02342600: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
|
|
| Withdrawn | 2 | 0 | NA | Pazopanib, Votrient, Trametinib, Mekinist | Sarcoma Alliance for Research through Collaboration, Novartis | Gastrointestinal Stromal Tumors | 01/20 | | | |
NCT01164228: Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 87 | US | Gemcitabine, 2'-Deoxy-2', 2'-difluorocytidine monohydrochloride, Gemzar, Sunitinib, SU011248 L-Malate salt, SU010398, PHA-290940AD, Sutent, SU011248 | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Kidney Cancer | 03/20 | 11/21 | | |
2018-004332-30: Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Etude évaluant l’efficacité du Lenvatinib chez des patients présentant un GIST localement avancé après échec de l’imatinib et du sunitinib |
|
|
| Not yet recruiting | 2 | 74 | Europe | E7080, Capsule, Lenvima | Centre Léon Bérard, EISAI SAS | Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib) Patients avec un GIST métastatique ou localement avancé, après échec du traitement par imatinib et sunitinib (en 3ème ligne de traitement ou au-delà d’une 3ème ligne par regorafenib), Patients with metastatic GIST Patients présentant un GIST métastatique, Diseases [C] - Cancer [C04] | | | | |
NCT01664182: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer |
|
|
| Completed | 2 | 41 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Pazopanib Hydrochloride, GW786034B, Votrient, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent, Trebananib, AMG 386, AMG386, Angiopoietin 1/2-Neutralizing Peptibody AMG 386 | National Cancer Institute (NCI) | Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 | 12/20 | 12/20 | | |
|
ChiCTR1800020407: Efficacy and safety of apapitatin mesylate in the treatment of metastatic gastrointestinal stromal tumor (GIST) with failed imatinib mesylate or sunitinib |
|
|
| Recruiting | 2 | 30 | | Apatinib 500mg qd | West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSCO Funding | Gastrointestinal stromal tumor | | | | |
NCT03641326: Sunitinib in Sarcomas of the Central Nervous System |
|
|
| Terminated | 2 | 5 | US | Sunitinib, Sutent, wGT3x-BT, Actigraph | National Cancer Institute (NCI) | Gliosarcoma, Central Nervous System Sarcoma | 04/21 | 04/21 | | |
NCT04633122: A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib |
|
|
| Completed | 2 | 108 | RoW | Ripretinib, DCC-2618, Sunitinib | Zai Lab (Shanghai) Co., Ltd. | Gastrointestinal Stromal Tumor(GIST) | 07/22 | 07/22 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
NCT03944304: Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. |
|
|
| Recruiting | 2 | 40 | RoW | Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 11/25 | 11/25 | | |
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma |
|
|
| Active, not recruiting | 2 | 34 | US | Cediranib, AZD2171 maleate, Recentin, AXD2171, Sunitinib, Sutent, SU11248, SU011248, Prochlorperazine, Compro, Promethazine, Phenadoz, Phenergan, Promethegan, Benzodiazepine, Valium, Diazepam, Estazolam, ProSom, Flurazepam, Dalmane, Lorazepam, Ativan, Filgrastim, Neupogen, Sargramostim, Leukine, Lomotil, Diphenoxylate hydrochloride (HCL)/atropine, Loperamide, Imodium, Diamode, Anti-Diarrheal (loperamide), Vitamin B6, Pyridoxine, Aquaphor, Acetaminophen, Tylenol, Ofirmev, FeverAll, Levothyroxine, Synthroid, Tirosint, Unithroid, Warfarin, Coumadin | National Cancer Institute (NCI) | Sarcoma, Alveolar Soft Part | 11/23 | 03/25 | | |
NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST |
|
|
| Recruiting | 2 | 40 | US | Bezuclastinib in combination with sunitinib | Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group | Gastrointestinal Stromal Tumors, GIST | 06/26 | 06/27 | | |
| Not yet recruiting | 2 | 28 | RoW | Liporaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 03/27 | 03/27 | | |
CABOSUN II, NCT03541902: Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 32 | US | Cabozantinib, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent | M.D. Anderson Cancer Center, Exelixis, National Cancer Institute (NCI) | Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma | 07/25 | 07/25 | | |
|
NCT05905887: Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor |
|
|
| Recruiting | 2 | 48 | RoW | Rivoceranib Mesylate, Paclitaxel | Asan Medical Center | Gastrointestinal Stromal Tumors | 08/26 | 12/26 | | |
NCT05366816: ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST |
|
|
| Recruiting | 2 | 48 | US | Sunitinib, Sutent, SU11248, Regorafenib, Stivarga, Regonix, BAY 73-4506 | University of Miami | Gastrointestinal Stromal Tumors | 12/26 | 12/28 | | |
ACTRN12608000474358: A phase IB/II study of sunitinib in combination with neoadjuvant radiation in patients with resectable soft tissue sarcoma |
|
|
| Recruiting | 1/2 | 26 | | | Peter MacCallum Cancer Centre, Pfizer Inc. | Soft tissue sarcoma | | | | |
NCT00457743: A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) |
|
|
| Completed | 1/2 | 36 | Japan | Sunitinib malate (SU011248) | Pfizer | Gastrointestinal Stromal Tumors | 08/08 | 08/08 | | |
| Unknown status | 1/2 | 26 | RoW | Sunitinib malate, Sutent, Radiotherapy | Australasian Sarcoma Study Group, Peter MacCallum Cancer Centre, Australia, Pfizer | Soft Tissue Sarcoma | 03/12 | 03/16 | | |
NCT03609424: PDR001 Plus Imatinib for Metastatic or Unresectable GIST |
|
|
| Completed | 1/2 | 39 | RoW | PDR001, Imatinib | Asan Medical Center, Novartis | Gastrointestinal Stromal Tumors | 11/21 | 11/21 | | |
NCT05160168: A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
|
|
| Terminated | 1/2 | 32 | US | THE-630 | Theseus Pharmaceuticals | Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases | 02/24 | 02/24 | | |
| Completed | 1/2 | 197 | Europe | Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate | Grupo Espanol de Investigacion en Sarcomas | Soft Tissue Sarcoma, Bone Sarcoma | 06/24 | 06/24 | | |
